Navamedic ASA (NAVA) - Net Assets
Based on the latest financial reports, Navamedic ASA (NAVA) has net assets worth Nkr334.08 Million NOK (≈ $35.15 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Nkr741.75 Million ≈ $78.05 Million USD) and total liabilities (Nkr407.67 Million ≈ $42.90 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check NAVA tangible net assets ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Nkr334.08 Million |
| % of Total Assets | 45.04% |
| Annual Growth Rate | 19.05% |
| 5-Year Change | 120.9% |
| 10-Year Change | 215.97% |
| Growth Volatility | 48.07 |
Navamedic ASA - Net Assets Trend (2003–2025)
This chart illustrates how Navamedic ASA's net assets have evolved over time, based on quarterly financial data. See how many days can Navamedic ASA fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Navamedic ASA (2003–2025)
The table below shows the annual net assets of Navamedic ASA from 2003 to 2025. For live valuation and market cap data, see Navamedic ASA market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Nkr334.08 Million ≈ $35.15 Million |
+38.95% |
| 2024-12-31 | Nkr240.44 Million ≈ $25.30 Million |
+8.11% |
| 2023-12-31 | Nkr222.39 Million ≈ $23.40 Million |
+6.04% |
| 2022-12-31 | Nkr209.72 Million ≈ $22.07 Million |
+38.67% |
| 2021-12-31 | Nkr151.24 Million ≈ $15.91 Million |
+16.80% |
| 2020-12-31 | Nkr129.49 Million ≈ $13.63 Million |
+63.43% |
| 2019-12-31 | Nkr79.23 Million ≈ $8.34 Million |
-20.23% |
| 2018-12-31 | Nkr99.32 Million ≈ $10.45 Million |
+2.71% |
| 2017-12-31 | Nkr96.70 Million ≈ $10.18 Million |
-8.54% |
| 2016-12-31 | Nkr105.73 Million ≈ $11.13 Million |
-10.61% |
| 2015-12-31 | Nkr118.28 Million ≈ $12.45 Million |
+6.34% |
| 2014-12-31 | Nkr111.23 Million ≈ $11.70 Million |
+3.71% |
| 2013-12-31 | Nkr107.26 Million ≈ $11.29 Million |
+10.95% |
| 2012-12-31 | Nkr96.68 Million ≈ $10.17 Million |
+3.69% |
| 2011-12-31 | Nkr93.24 Million ≈ $9.81 Million |
-6.95% |
| 2010-12-31 | Nkr100.21 Million ≈ $10.54 Million |
-10.36% |
| 2009-12-31 | Nkr111.78 Million ≈ $11.76 Million |
+1.40% |
| 2008-12-31 | Nkr110.24 Million ≈ $11.60 Million |
-14.54% |
| 2007-12-31 | Nkr128.99 Million ≈ $13.57 Million |
+111.93% |
| 2006-12-31 | Nkr60.87 Million ≈ $6.40 Million |
+40.93% |
| 2005-12-31 | Nkr43.19 Million ≈ $4.54 Million |
+126.94% |
| 2004-12-31 | Nkr19.03 Million ≈ $2.00 Million |
+163.94% |
| 2003-12-31 | Nkr7.21 Million ≈ $758.70K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Navamedic ASA's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 71.8% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Nkr1.88 Million | 0.56% |
| Common Stock | Nkr17.75 Million | 5.31% |
| Other Components | Nkr314.45 Million | 94.13% |
| Total Equity | Nkr334.08 Million | 100.00% |
Navamedic ASA Competitors by Market Cap
The table below lists competitors of Navamedic ASA ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Obase Bilgisayar ve Danismanlik Hizmetleri Ticaret A.S.
IS:OBASE
|
$42.90 Million |
|
Metagenomi, Inc. Common Stock
NASDAQ:MGX
|
$42.92 Million |
|
Modernform Group Public Company Limited
BK:MODERN
|
$42.92 Million |
|
Inventus Mining Corp
V:IVS
|
$42.92 Million |
|
AXIOS Sustainable Growth
NYSE:AXAC
|
$42.88 Million |
|
Idex ASA
OL:IDEX
|
$42.88 Million |
|
Duck Yang Ind
KO:024900
|
$42.87 Million |
|
SunCar Technology Group Inc.
NASDAQ:SDA
|
$42.87 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Navamedic ASA's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 240,437,000 to 334,077,000, a change of 93,640,000 (38.9%).
- Net loss of 23,538,000 reduced equity.
- Share repurchases of 130,202,000 reduced equity.
- New share issuances of 130,202,000 increased equity.
- Other comprehensive income decreased equity by 1,000.
- Other factors increased equity by 117,179,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Nkr-23.54 Million | -7.05% |
| Share Repurchases | Nkr130.20 Million | -38.97% |
| Share Issuances | Nkr130.20 Million | +38.97% |
| Other Comprehensive Income | Nkr-1.00K | -0.0% |
| Other Changes | Nkr117.18 Million | +35.08% |
| Total Change | Nkr- | 38.95% |
Book Value vs Market Value Analysis
This analysis compares Navamedic ASA's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.22x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 10.53x to 1.22x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2003-12-31 | Nkr1.61 | Nkr17.00 | x |
| 2004-12-31 | Nkr4.26 | Nkr17.00 | x |
| 2005-12-31 | Nkr9.67 | Nkr17.00 | x |
| 2006-12-31 | Nkr10.70 | Nkr17.00 | x |
| 2007-12-31 | Nkr20.33 | Nkr17.00 | x |
| 2008-12-31 | Nkr14.60 | Nkr17.00 | x |
| 2009-12-31 | Nkr14.61 | Nkr17.00 | x |
| 2010-12-31 | Nkr13.27 | Nkr17.00 | x |
| 2011-12-31 | Nkr11.88 | Nkr17.00 | x |
| 2012-12-31 | Nkr11.54 | Nkr17.00 | x |
| 2013-12-31 | Nkr12.47 | Nkr17.00 | x |
| 2014-12-31 | Nkr12.98 | Nkr17.00 | x |
| 2015-12-31 | Nkr13.45 | Nkr17.00 | x |
| 2016-12-31 | Nkr10.27 | Nkr17.00 | x |
| 2017-12-31 | Nkr8.88 | Nkr17.00 | x |
| 2018-12-31 | Nkr9.13 | Nkr17.00 | x |
| 2019-12-31 | Nkr6.76 | Nkr17.00 | x |
| 2020-12-31 | Nkr8.95 | Nkr17.00 | x |
| 2021-12-31 | Nkr1.89 | Nkr17.00 | x |
| 2022-12-31 | Nkr12.32 | Nkr17.00 | x |
| 2023-12-31 | Nkr12.63 | Nkr17.00 | x |
| 2024-12-31 | Nkr13.61 | Nkr17.00 | x |
| 2025-12-31 | Nkr13.93 | Nkr17.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Navamedic ASA utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.05%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -4.16%
- • Asset Turnover: 0.76x
- • Equity Multiplier: 2.22x
- Recent ROE (-7.05%) is below the historical average (-2.68%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2003 | 6.72% | 556.84% | 0.11x | 0.11x | Nkr-236.55K |
| 2004 | 27.76% | 451.51% | 0.07x | 0.90x | Nkr3.38 Million |
| 2005 | -11.27% | -109.81% | 0.09x | 1.11x | Nkr-9.19 Million |
| 2006 | -12.44% | -1959.38% | 0.01x | 0.86x | Nkr-13.66 Million |
| 2007 | -2.49% | -10.09% | 0.17x | 1.44x | Nkr-16.11 Million |
| 2008 | -7.33% | -17.52% | 0.29x | 1.45x | Nkr-19.10 Million |
| 2009 | 11.46% | 24.37% | 0.39x | 1.22x | Nkr1.64 Million |
| 2010 | -11.16% | -20.31% | 0.45x | 1.23x | Nkr-21.21 Million |
| 2011 | -7.68% | -10.04% | 0.51x | 1.49x | Nkr-16.48 Million |
| 2012 | -3.37% | -3.67% | 0.66x | 1.38x | Nkr-12.92 Million |
| 2013 | -1.18% | -0.84% | 0.85x | 1.67x | Nkr-11.99 Million |
| 2014 | 1.17% | 0.59% | 1.05x | 1.92x | Nkr-9.82 Million |
| 2015 | -9.24% | -4.40% | 0.90x | 2.33x | Nkr-22.76 Million |
| 2016 | -10.08% | -3.89% | 0.95x | 2.72x | Nkr-21.23 Million |
| 2017 | -16.07% | -6.03% | 1.04x | 2.56x | Nkr-25.21 Million |
| 2018 | 7.33% | 3.96% | 0.86x | 2.16x | Nkr-2.65 Million |
| 2019 | -20.57% | -8.63% | 1.01x | 2.36x | Nkr-24.22 Million |
| 2020 | -12.71% | -7.84% | 0.81x | 2.01x | Nkr-29.41 Million |
| 2021 | 0.41% | 0.22% | 0.84x | 2.18x | Nkr-14.51 Million |
| 2022 | 14.03% | 7.70% | 1.00x | 1.83x | Nkr8.46 Million |
| 2023 | 1.49% | 0.65% | 0.98x | 2.36x | Nkr-18.94 Million |
| 2024 | 0.54% | 0.24% | 1.08x | 2.04x | Nkr-22.75 Million |
| 2025 | -7.05% | -4.16% | 0.76x | 2.22x | Nkr-56.95 Million |
Industry Comparison
This section compares Navamedic ASA's net assets metrics with peer companies in the Medical Distribution industry.
No peer company data available for comparison.
About Navamedic ASA
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. Its product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. The company offers medical nutrition… Read more